Table 1 Rates of antimicrobial resistance in Gram-negative bacilli responsible for hospital-acquired infections
From: Mechanisms of antimicrobial resistance in Gram-negative bacilli
Study/surveillance network | INICC [3] | SENTRY [9] | ANSRPRG [8] | EARS-NET [5] |
|---|---|---|---|---|
Geographic area | International (36 countries) | International (Europe/USA) | International (Asia) | International (Europe) |
Study years | 2004–2009 | 2009–2011 | 2008–2009 | 2013 |
Setting | ICU | ICU | ICU/non-ICU | ICU/non-ICU |
Type of hospital-acquired infections | Catheter-related infections and ventilator-associated pneumonia | All (pooled) | Pneumonia | Bloodstream infections |
Species/antimicrobial | ||||
 Escherichia coli | ||||
  Fluoroquinolones | 53% | 30% | – | 11–52% |
  3GC | 67% | 13% | – | 5–40% |
  Carbapenems | 4% | <1% | – | 0–3% |
 Klebsiella pneumoniae | ||||
  Fluoroquinolones | – | 17% | 31% | 0–70% |
  3GC | 72% | 19% | 43% | 0–70% |
  Carbapenems | 7% | 4% | 2% | 0–59% |
 Pseudomonas aeruginosa | ||||
  Fluoroquinolones | 45% | 30% | 30% | 0–53% |
  Aminoglycosides | 28% | 17%a | – | 0–51% |
  Piperacillin–tazobactam | 39% | 32% | 37% | 0–55% |
  Ceftazidime | – | 27% | 35% | 0–44% |
  Carbapenems | 45% | 30%b | 30% | 3–60% |
 Acinetobacter baumannii | ||||
  Ceftazidime | – | 63% | – | – |
  Carbapenems | 63% | 57%b | 67% | 0–90% |